Benactyzine
Chemical compound
- none
- 2-(diethylamino)ethyl hydroxy(diphenyl)acetate
- 302-40-9
Y
- 9330
- DB09023
N
- 8966 Y
- 595EG71R3F
- D07498 Y
- ChEMBL70352 Y
- DTXSID0022644
- Interactive image
- O=C(OCCN(CC)CC)C(O)(c1ccccc1)c2ccccc2
InChI
- InChI=1S/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3Y
- Key:IVQOFBKHQCTVQV-UHFFFAOYSA-NY
N
Y (what is this?) (verify)Benactyzine is an anticholinergic drug that was used in the treatment of clinical depression and anxiety disorders before it was pulled from the U.S. market by the FDA due to serious side effects.[2]
Its use for these indications was limited by side effects such as dry mouth and nausea, and at high doses it can cause more severe symptoms such as deliriant and hallucinogenic effects.[2] "Large doses of benactyzine in normal subjects may produce a state resembling the action of mescaline or LSD."[3]
Brand names have included: Suavitil, Phebex, Phobex, Cedad, Cevanol, Deprol, Lucidil, Morcain, Nutinal, Parasan. While there was some tentative evidence of effectiveness when combined with meprobamate, with the medication no longer available it is not clinically important.[4]
History
Benactyzine was brought to market in the US in 1957 by Merck under the tradename, Suavitil.[5]
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ a b Shorter E (December 2002). "Looking backwards: a possible new path for drug discovery in psychopharmacology". Nature Reviews. Drug Discovery. 1 (12): 1003–1006. doi:10.1038/nrd964. PMID 12461521. S2CID 23439533.
- ^ Fisher S (1959). Child Research In Psychopharmacology (1st ed.). Springfield, Illinois: Charles C Thomas Pub. p. 13.
- ^ DeBattista AF, Schatzberg JO, Cole C (2010). Manual of clinical psychopharmacology (7th ed.). Washington, DC: American Psychiatric Pub. p. 423. ISBN 978-1-58562-377-8.
- ^ Smith MC (2013). "Market Behavior". Principles of Pharmaceutical Marketing (Third ed.). New York: Routledge. ISBN 978-1-317-94071-5.
External links
Media related to Benactyzine at Wikimedia Commons
- v
- t
- e
Specific reuptake inhibitors and/or receptor modulators | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||
| |||||||
| |||||||
Miscellaneous | |
|---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
